Show simple item record

dc.contributor.authorBanfill, Kathryn
dc.contributor.authorPrice, G
dc.contributor.authorWicks, K
dc.contributor.authorAhmad, S.
dc.contributor.authorBainbridge, H.
dc.contributor.authorBayne, M.
dc.contributor.authorBritten, A.
dc.contributor.authorCarson, C.
dc.contributor.authorDorey, N.
dc.contributor.authorGoranov, B.
dc.contributor.authorGuglani, S.
dc.contributor.authorHarland, K.
dc.contributor.authorHatton, M.
dc.contributor.authorJayaprakash, K. T.
dc.contributor.authorHiley, C.
dc.contributor.authorJegannathen, A.
dc.contributor.authorKoh, P.
dc.contributor.authorLord, H.
dc.contributor.authorMokhtar, D.
dc.contributor.authorPanakis, N.
dc.contributor.authorPeedell, C.
dc.contributor.authorPope, T.
dc.contributor.authorPeters, A.
dc.contributor.authorPowell, C.
dc.contributor.authorStilwell, C.
dc.contributor.authorTreece, S.
dc.contributor.authorThomas, B.
dc.contributor.authorToy, E.
dc.contributor.authorZhou, S. Y
dc.contributor.authorFaivre-Finn, Corinne
dc.date.accessioned2021-07-28T12:41:42Z
dc.date.available2021-07-28T12:41:42Z
dc.date.issued2021en
dc.identifier.citationBanfill KB, Price G, Wicks K, Ahmad S, Bainbridge H, Bayne M, et al. Changes in management for patients with lung cancer referred for radical radiotherapy during the first wave of the COVID 19 pandemic in the UK (COVID-RT Lung). Lung Cancer . 2021 Jun;156:S14.en
dc.identifier.urihttp://hdl.handle.net/10541/624176
dc.description.abstractIntroduction: In response to the COVID-19 pandemic, guidelines on reduced fractionation for patients with lung cancer treated with curative-intent radiotherapy (RT) were published, aiming to reduce the number of hospital attendances and potential exposure of vulnerable patients to SARS-CoV-2. Here we describe the changes that have taken place. Methods: COVID-RT Lung is a prospective, multicentre UK data collection. Inclusion criteria are: patients with stage 1–3 lung cancer referred for radical RT between 2/4/2020–2/10/2020. Both patients who had a change in their management and those who continue with standard management are included. Data on demographics, COVID-19 diagnosis, diagnostic work-up, RT and systemic treatment, treatment-related toxicity, disease/patient status are collected. Each participating centre obtains local approval to collect data. Anonymised data are collected on a central, cloud-based Research Electronic Data Capture system. Results: 1551 records from 30 UK RT sites were available for analysis on 17/3/2021. 759 (49%) female, median age 72 years (37- 93 years). 641 patients (41%) had stage 3 disease. 489 patients (31%) had a radiological diagnosis of lung cancer and 909 (59%) had NSCLC. 21 patients (1.4%) were diagnosed with COVID-19, 6 during radiotherapy. 193 patients (12%) had their diagnostic investigations affected by the pandemic. 527 patients (34%) had their treatment changed from their centre’s standard of care. 257 patients (16.6%) had a change to their radiotherapy regimen; chemotherapy was omitted in 82 patients (5.3%) and reduced in 70 (4.5%). Analysing variations across the UK (Fig. 1), the North West of England had the highest proportion of patients who had their treatment changed from their centre’s standard of care (48%). Conclusion: This nationwide cohort shows that clinicians in the UK changed the management of patients with stage 1–3 lung cancer in line with national guidelines. Regions with high rates of COVID-19 changed management of a greater proportion of patients.en
dc.language.isoenen
dc.titleChanges in management for patients with lung cancer referred for radical radiotherapy during the first wave of the COVID 19 pandemic in the UK (COVID-RT Lung)en
dc.typeMeetings and Proceedingsen
dc.contributor.departmentThe Christie NHS Foundation Trust, Manchesteren
dc.identifier.journalLung Canceren
dc.description.noteen]


This item appears in the following Collection(s)

Show simple item record